BASALIT trial: double‐blind placebo‐controlled allergen immunotherapy with rB et v 1‐FV in birch‐related soya allergy
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Conflicting results exist on the effect of allergen immunotherapy (AIT) on pollen‐related food allergy. We aimed to investigate the efficacy of one‐year AIT with the folding variant (FV) of recombinant (r) Bet v 1 on birch‐related soya allergy. Methods: Of 138 subjects with Bet v 1 sensitization, 82 were positive at double‐blind placebo‐controlled food challenge (DBPCFC) with soya. A total of 56 of 82 were randomized in the ratio of 2:1 (active: placebo). Per‐protocol population (PPP) had received ≥150 μg of allergen or placebo preparation. Outcome measures: lowest observed adverse effect levels (LOAEL), postinterventional occurrence of objective signs (objS) at any dose level, sIgE/IgG4 against Bet v 1 and Gly m 4. Between‐group changes were investigated (ancova, Mann–Whitney U‐test, Fisher exact test). Results: Baseline characteristics including LOAEL s were comparable in both groups with objS and subjS occurring in 82% and 95% of active (n = 38) vs 78% and 83% of placebo group (n = 18). After AIT, objS occurred in 24% and 47%, respectively. LOAEL group differences showed a beneficial tendency (P = 0.081) for LOAELobjective in PPP (30 active, 15 placebo). sIgG 4 raised only in active group (Bet v 1: P = 0.054, Gly m 4: P = 0.037), and no relevant changes occurred for sIgE. Only 56% of the intended sample size was recruited. Conclusion: For the first time, we present data on the effect of rB et v 1‐FV on birch‐related soya allergy. rB et v 1‐FV AIT induced significant immunogenic effects. Clinical assessment showed a tendency in favour of the active group but did not reach statistical significance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Asero (1998) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.1998.00399.x · Cited by 195
Bolhaar, S. T. H. P., Tiemessen, M. M., Zuidmeer, L., Van Leeuwen, A., Hoffmann‐Sommergruber, K., Bruijnzeel‐Koomen, C. A. F. M., Taams, L. S., Knol, E. F., Van Hoffen, E., Van Ree, R., et al. (2004) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2004.1939.x · Cited by 172
Overview of Component Resolved Diagnostics
Treudler, R., & Simon, J. C. (2013) · Current Allergy and Asthma Reports · doi:10.1007/s11882-012-0318-8 · Cited by 109
Self-citationBirch-Apple Syndrome Treated with Birch Pollen Immunotherapy
Mauro, M., Russello, M., Incorvaia, C., Gazzola, G., Frati, F., Moingeon, P., & Passalacqua, G. (2011) · International Archives of Allergy and Immunology · doi:10.1159/000323909 · Cited by 90 · cited 1×
“It was suggested that doses to induce an appreciable effect of birch pollen AIT on pollen-related FA should be higher than those sufficient to improve pollen-related respiratory symptoms (16, 18, 21).”
BackgroundMeyer, W., Narkus, A., Salapatek, A. M., & Häfner, D. (2013) · Allergy · doi:10.1111/all.12148 · Cited by 72 · cited 3×
“The rBet v 1-FV extract was well tolerated, and, as in previous trials (22, 35), the safety profile was comparable with placebo; no rBet v 1-FV-related severe adverse effects occurred.”
BackgroundResult
Cited by
Birch Pollen Allergy in Europe
Biedermann, T., Winther, L., Till, S. J., Panzner, P., Knulst, A., & Valovirta, E. (2019) · Allergy · doi:10.1111/all.13758 · Cited by 310
Self-citationGuan, K., Li, L., & Chang, C. (2022) · Current Protein & Peptide Science · doi:10.2174/1389203723666220815095725 · Cited by 19
Kallen, E. J. J., Welsing, P. M. J., Löwik, J. M., Van Ree, R., Knulst, A. C., & Le, T. M. (2024) · Frontiers in Allergy · doi:10.3389/falgy.2024.1360073 · Cited by 12
Metadata
- Authors
- Treudler, R., Franke, A., Schmiedeknecht, A., Ballmer‐Weber, B., Worm, M., Werfel, T., Jappe, U., Biedermann, T., Schmitt, J., Brehler, R., Kleinheinz, A., Kleine‐Tebbe, J., Brüning, H., Ruëff, F., Ring, J., Saloga, J., Schäkel, K., Holzhauser, T., Vieths, S., & Simon, J. C.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2017-01-17
- Volume
- 72
- Issue
- 8
- Pages
- 1243-1253
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2564197934
- Cited by
- 47
- References
- 5
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.